ENOV vs. ESTA, AVNS, SNN, CORT, TNDM, ARWR, NEOG, LFST, LTH, and DNLI
Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Establishment Labs (ESTA), Avanos Medical (AVNS), Smith & Nephew (SNN), Corcept Therapeutics (CORT), Tandem Diabetes Care (TNDM), Arrowhead Pharmaceuticals (ARWR), Neogen (NEOG), LifeStance Health Group (LFST), Life Time Group (LTH), and Denali Therapeutics (DNLI). These companies are all part of the "medical" sector.
Establishment Labs (NASDAQ:ESTA) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
In the previous week, Enovis had 3 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for Enovis and 1 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.44 beat Enovis' score of 0.00 indicating that Enovis is being referred to more favorably in the news media.
Establishment Labs currently has a consensus price target of $55.00, indicating a potential downside of 2.78%. Enovis has a consensus price target of $75.43, indicating a potential upside of 43.92%. Given Establishment Labs' higher probable upside, analysts clearly believe Enovis is more favorable than Establishment Labs.
Establishment Labs received 88 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 62.22% of users gave Establishment Labs an outperform vote while only 60.00% of users gave Enovis an outperform vote.
Enovis has higher revenue and earnings than Establishment Labs. Enovis is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.
72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 11.4% of Establishment Labs shares are held by insiders. Comparatively, 2.4% of Enovis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Establishment Labs has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.
Enovis has a net margin of -4.51% compared to Enovis' net margin of -53.12%. Establishment Labs' return on equity of 3.98% beat Enovis' return on equity.
Summary
Enovis beats Establishment Labs on 12 of the 17 factors compared between the two stocks.
Get Enovis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
